Category: Cell Line Development

Promoter Evaluation in the Cellca CHO DG44 Expression System

4th December 2017

Category: Cell Line Development

Tags: ,

By: Ann-Catherin Leroux - Scientist, Dr Christoph Zehe - Lead Scientist,

One key component of the powerful Cellca Expression Platform is the expression vector. We have carefully selected its genetic elements to allow: freedom to operate high level expression of monomeric and dimeric products (e.g. IgG-type antibodies, Fc-Fusion, bispecifics) enhanced, stable expression by optimized S/MAR elements increased secretion by optimized signal peptide As a next step More

Improved Speed to Clinic by Increasing Automation in Cell Line Development

14th November 2017

Category: Cell Line Development

Tags: , ,

By: Dr Christoph Zehe - Lead Scientist, Dr Monika Holeiter - Senior Scientist, Technology Development,

“Speed to Clinic” is a crucial measure for successful drug development. As a leading provider of stable cell lines, Sartorius Stedim Cellca strives to contribute to this goal by increasing the degree of automation in its Cell Line Development (CLD) technology. While maintaining consistently high quality of the recombinant products, we develop an automation strategy More

Proving Clonality of Cell Lines with 99.9% Probability

21st September 2017

Category: Cell Line Development

Tags: , ,

By: Dr Christoph Zehe - Lead Scientist,

Proving clonality of production cell lines is an important topic in the field of cell line development. The main regulatory authorities and organizations, such as the Food and Drug Administration (FDA) require detailed evidence of monoclonality of production cell lines. Failing to provide sufficient evidence of monoclonality will require additional manufacturing controls, which can lead More

Improved Clone Evaluation and Selection of CHO Cell Lines using ambr15®

8th August 2017

Category: Cell Line Development

Tags:

By: Anton Stefan - Scientist, Dirk Mueller - Team Leader, Dr Christoph Zehe - Lead Scientist, Michael Grauf - Scientist,

The global market for biopharmaceutical products continues to expand, making it a highly attractive market for biopharmaceutical companies. Due to the rising number of projects with variant protein drug candidate molecules, increasing productivity of cell culture process development to support material production for early phase clinical trials has been an important task in recent years. More

Cell Line Development (CLD) 2.0

6th July 2017

Category: Cell Line Development

Tags: ,

By: Caroline Hauser - Team Leader, Dr Christoph Zehe - Lead Scientist, Juliana Schubert - Scientist, Kristin Thiele - Scientist,

The production of biologics in Chinese Hamster Ovary cells (CHO) is becoming more and more challenging due to an increasing number of complex and difficult-to-express (DTE) molecules. Nevertheless, general Cell Line Development (CLD) platform processes should provide reliable high-titer cell lines irrespective of the therapeutic protein formats to be expressed. In the last 20 years More

How to achieve high-yielding cell lines

30th May 2017

Category: Cell Line Development

Tags: , , ,

By: Caroline Hauser - Team Leader, Dr Christoph Zehe - Lead Scientist, Juliana Schubert - Scientist, Nico Erb - Scientist,

The global market for biological products is expected to reach $287bn by the end of 2020. There are many drivers for the continued investment and development of therapeutic protein products, such as: an increase in incidences of cancer and autoimmune diseases, reduction in side effects, advances in technology and patent expiry of blockbuster drugs. Although More

Preparing for future bioprocessing challenges with the Cellca CHO Expression Platform

13th July 2016

Category: Cell Line Development

Tags: ,

By: Dr. Brian Wendelburg, Sr. Field Marketing Manager,

Therapeutic protein development and production is a very technically challenging, time consuming and expensive endeavor. What are some of the challenges? There are numerous critical decisions that must be made with regard to mammalian cell line choice (CHO, NS0, etc.), appropriate gene and marker expression systems, cell culture medium and feed optimization, clone selection and More

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy